Colorectal cancer is rising sharply in adults under 50, with unclear causes but growing links to diet, lifestyle, and environmental exposure. Experts urge earlier screening and renewed scrutiny of ultra‑processed foods, alcohol, and other risk factors shaping consumer health.
Celsius has evolved into a bona fide energy drink heavyweight, yet its stock still whipsaws like a speculative upstart. Investors remain torn over brand momentum, margin pressure, and whether Alani and Rockstar can deliver durable, Monster level staying power.
Sweet proteins may be 1,000 times sweeter than sugar, but they don’t spike blood glucose, and food-tech startups are betting big on their future. With FDA clearances rolling in and fermentation scaling up, these novel ingredients could reshape sugar reduction strategies across the industry.
Competition from less expensive weight-loss drugs has prompted Danish drugmaker Novo Nordisk A/S to announce cuts to pricing for GLP-1 products Wegovy and Ozempic. Novo’s GLP-1s will cost $675 a month across the board, down …
